Core Insights - Glucotrack, Inc. has established a Patient Advisory Board (PAB) to incorporate patient perspectives into the development of its long-term implantable Continuous Blood Glucose Monitor (CBGM) technology [1][2][3] - The PAB consists of individuals with diabetes who will provide insights on the challenges of diabetes management, influencing all stages of the CBGM's development from clinical trials to commercialization [2][3] - The CBGM is designed to offer continuous, accurate blood glucose monitoring for up to three years without a wearable component, measuring glucose directly from blood rather than interstitial fluid [4][7] Company Overview - Glucotrack, Inc. focuses on the design, development, and commercialization of innovative technologies for diabetes management [6] - The company is currently developing a long-term implantable continuous blood glucose monitoring system aimed at improving the convenience and accuracy of glucose monitoring for individuals with diabetes [6][7] Product Details - The CBGM system is characterized by its long-term implantable nature, sensor longevity of three years, and minimal calibration requirements [4][7] - Unlike traditional systems, the CBGM provides real-time glucose readings without the lag associated with interstitial fluid measurements, enhancing the user experience [4]